CAP-Ketamine for Antidepressant Resistant PTSD

• Status: Completed
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Collaborators: Brooke Army Medical Center; Minneapolis Veterans Affairs Medical Center; The University of Texas Health Science Center at San Antonio
• Treatments: Antidepressive Agents; Ketamine

Criteria

Inclusion Criteria:

• male or female Veterans or active duty military personnel between the ages of 18 and 70 years

• diagnosis of PTSD

• history of trialing one or more antidepressant medications with little to no PTSD symptom improvement

• ability to provide written informed consent

Exclusion Criteria:

• females who are currently pregnant or breastfeeding

• current high risk for suicide

• history of severe head injury